Send me real-time posts from this site at my email

Idera Pharma - Massive Upside

Idera Pharmaceuticals (IDRA)

IDRA is a tiny biotech trading below $2.00 per share, its a very volatile stock, we may be about to see another massive rally soon. 


This stock is compelling because of the sheer volume of growth catalysts that are coming out by the end of the year. 

Catalyists for Growth 

  1. Waldenström’s Macroglobulinemia (WM) A Phase 1/2 clinical trial of IMO-8400 -
  2. Diffuse Large B-cell Lymphoma (DLBCL) A Phase 1/2 clinical trial of IM0-8400
  3. Metastatic Melanoma A Phase 1/2 clinical trial of intratumoral IMO-2125 in combination with ipilimumab (a CTLA4 antibody) in patients with metastatic melanoma is underway.
  4. DERMATOMYOSITIS A randomized, double-blind, placebo-controlled Phase 2 clinical trial of IMO-8400 in dermatomyositis has recently been initiated to assess the compound’s safety.

Risks: 

Stock dilution 

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue